Oxford Cannabinoid Technologies is a medicinal cannabis company focused on developing pain relief treatments using cannabinoids.
It has licenced one compound from a Japanese pharma firm and is developing other compounds. Phase 1 trials are expected later next year for the licenced compound and possibly another one. As the prospectus says, fewer than 10% of phase 1 clinical trial molecules end up as an approved drug.
Imperial Brands owns 10.87% of the company and has been a shareholder since January 2018. The University of Oxford has said that it will not enter into any other projects wi...
